Protein farnesyl transferase as a target for the development of anticancer drugs

Drugs of the Future

Volumn 25, Issue 10, 2000, Pages 1069-1079

  Adjei, A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; A 176120; ANTINEOPLASTIC AGENT; BMS 186511; EPOTHILONE DERIVATIVE; L 778123; LONAFARNIB; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG;

ANIMAL CELL; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME MECHANISM; FATIGUE; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MOUSE; NEUROPATHY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN MODIFICATION; REVIEW;

EID: 0033637047     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.10.659165     Document Type: Review

References (98)

1. Human lamin B contains a farnesylated cysteine residue
2. The processing pathway of prelamin A
3. Isoprenylation of a protein kinase. Requirement of farnesylation/α-carboxyl methylation for full enzymatic activity ofrhodopsin kinase
4. The γ subunit of transducin is farnesylated
5. Function and regulation of Ras
6. Ras signalling and apoptosis
7. Ras oncogenes in human cancer: A review
8. Isoprenoid addition to Ras proteins is the critical modification for its membrane association and transforming activity
9. Recent advances in the study of prenylated proreins
10. Regulation of the mevalonate pathway
11. Enzymatic modification of proteins with a geranylgeranyl isoprenoid
12. A protein geranylgeranyltransferase from bovine brain: Implications for protein prenylation specificity
13. Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys
14. Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A
15. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues
16. Friends and family: The role of the Rab GTPases in vesicular traffic
17. cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase
18. FTIs block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules
19. Farnesylcysteine, a constituent of the α and α subunits of rabbit skeletal muscle phosphorylase kinase: Localization by conversion to S-ethylcysteine and by tandem mass spectrometry
20. Characterization of HDJ-2, a human 40 kD heat shock protein
21. Membrane association and targeting of prenylated Ras-like GTPases
22. PxF, a prenylated protein of peroxisomes
23. Prenylation of oncogenic human PTP (CAAX) protein tyrosine phosphatases
24. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution
25. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate
26. Inhibition of purified p21 ras farnesyl: Protein transferase by Cys-AAX tetrapeptides
27. Mutational analysis of conserved residues of the β-subunit of human farnesyl: Protein transferase
28. +-farnesyltransferase indicates metal coordination of the substrate thiolate
29. Sequence dependence of protein isoprenylation
30. Sequence requirement for peptide recognition by rat brain p21 ras protein farnesyltransferase
31. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase
32. Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release
33. Ras protein famesyltransferase: A strategic target for anticancer therapeutic development
34. Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway
35. Inhibition of ras-targeted prenylation: Protein farnesyltransferase inhibitors revisited
36. ras-p21-induced cell transformation: Unique signal transduction pathways and implications for the design of new chemotherapeutic agents
37. Biochemistry of protein prenylation
38. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
39. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
40. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
41. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells
42. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
43. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells
44. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
45. In vivo evaluation of farnesyltransferase inhibitor, PD169451
46. RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor with in vivo activity
47. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue
48. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells
49. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype
50. Rho family proteins and Ras transformation: The RHOad less traveled gets congested
51. Increasing complexity of Ras signaling
52. Signal transduction. How receptors turn Ras on
53. Ras genes
54. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type 1
55. The CAAXpeptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated oncogenic ras signaling and transformation
56. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
57. Farnesyltransferase inhibitors - Anti-ras or anticancer drugs?
58. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts
59. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments
60. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors
61. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
62. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
63. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
64. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
65. 1 and induces p21 (WAF1/CIP1/SDI1) in a p53-independent manner
66. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
67. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
68. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors
69. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli
70. The farnesyl transferase inhibitor SCH 66336 induces cell cycle changes in sensirive human tumor cell lines and prevents the farnesylation of the centromere associated proteins CENP-E and CENP-F
71. Farnesyltransferase inhibitors: Targeting the molecu' lar basis of cancer
72. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
73. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
74. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied Substratum attachment
75. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity
76. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
77. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
78. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of famesyl protein transferase, in human tumor xenograft models and Wap-Ras transgenic mice
79. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
80. Inhibition of human tumor xenograft growth by treatment with the famesyltransferase inhibitor B956
81. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGF α/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
82. Use of farnesyl transferase inhibitor Rl15777 in relapsed and refractory acute leukemias: Results of a phase 1 trial
83. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
84. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
85. Phase I clinical trial of the farnesyltransferase inhibitor BMS214662 in patients with advanced solid tumors
86. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor Rl15777 in advanced cancer
87. Phase I clinical and pharmacokinetic trial of the famesyttransferase inhibitor R115777 on a 21-day dosing schedule
88. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777
89. Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2week on, 2-week off schedule
90. Phase 1 and pharmacologic study of continuous daily oral SCH66336, a novel famesyl transferase inhibitor, in patients with solid tumors
91. The farnesyl prorein transferase (FPTase) inhibitor L-778123 in patients with solid cancers
92. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
93. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase. Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
94. Aphase I and pharmacokinetic study of the farnesyl transferase inhibitor R115777 in combination with gemcitabine
95. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers
96. A phase I and PK study of farnesyl transferase inhibitor L-778123 administered as a seven day Continuous infusion in combination with paclitaxel in patients with solid cancers
97. p21ras Activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein
98. Comparison of potential markers of farnesyltransferase inhibition